LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Search

Cara Therapeutics Inc

Ouvert

Secteur Soins de santé

0.25 -7.41

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.24

Max

0.28

Chiffres clés

By Trading Economics

Ventes

3M

BPA

-0.59

Employés

55

Dividendes

By Dow Jones

Prochains Résultats

11 nov. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.3M

46M

Ouverture précédente

7.66

Clôture précédente

0.25

Sentiment de l'Actualité

By Acuity

21%

79%

51 / 389 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Cara Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2024, 23:02 UTC

Actualités

Australian Consumer-Confidence Recovery Still Intact Amid Building Rate-Cut Hopes

28 oct. 2024, 23:01 UTC

Principaux Mouvements du Marché

Lithium Americas Shares Rise After News of DOE Loan

28 oct. 2024, 22:40 UTC

Résultats

Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26

28 oct. 2024, 22:29 UTC

Résultats

Waste Management Posts Revenue Growth on Price Increases

28 oct. 2024, 23:52 UTC

Actualités

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- Update

28 oct. 2024, 23:42 UTC

Market Talk

Lithium Spodumene Prices Have Likely Bottomed -- Market Talk

28 oct. 2024, 23:07 UTC

Actualités

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- WSJ

28 oct. 2024, 23:00 UTC

Résultats

WuXi AppTec 3Q Rev CNY10.46B, Down 2% on Year >603259.SH

28 oct. 2024, 22:59 UTC

Résultats

WuXi AppTec 3Q Net CNY2.29B , Down 17% on Year >603259.SH

28 oct. 2024, 22:15 UTC

Résultats

Sandfire Resources Net Debt $345 Million at End-Sept

28 oct. 2024, 22:15 UTC

Résultats

Sandfire Resources 1Q Underlying Ebitda $121 Million

28 oct. 2024, 22:15 UTC

Résultats

Sandfire Resources 1Q Unaudited Sales Revenue $282 Million

28 oct. 2024, 22:14 UTC

Résultats

Sandfire Resources 1Q Underlying Operating Cost of $78/Ton of Ore Processed at Matsa Operation

28 oct. 2024, 22:14 UTC

Résultats

Sandfire Resources 1Q Underlying Operating Cost of $40/Ton of Ore Processed at Motheo Operation

28 oct. 2024, 22:13 UTC

Résultats

Sandfire Resources Says Copper Equivalent Output at Matsa Operation Up 4% in 1Q

28 oct. 2024, 22:13 UTC

Résultats

Sandfire Resources Reaffirms FY 2025 Output, Cost, Capex Guidance

28 oct. 2024, 22:12 UTC

Résultats

Sandfire Resources 1Q Silver Output 1.3 Million Oz, Up 9% on Quarter

28 oct. 2024, 22:12 UTC

Résultats

Sandfire Resources 1Q Lead Output 2,081 Tons, Up 9% on Quarter

28 oct. 2024, 22:12 UTC

Résultats

Sandfire Resources 1Q Zinc Output 21,542 Tons, Down 1% on Quarter

28 oct. 2024, 22:11 UTC

Résultats

Sandfire Resources 1Q Copper Output 27,012 Tons, Down 1% on Quarter

28 oct. 2024, 22:11 UTC

Résultats

Sandfire Resources 1Q Copper Equivalent Output 38,000 Tons, Flat on Quarter

28 oct. 2024, 22:07 UTC

Résultats

China Southern Airlines: Strong Travel Demand Supported Results >1055.HK

28 oct. 2024, 22:07 UTC

Résultats

China Southern Airlines 9-Mos Rev CNY134.66B Vs. CNY119.49B >1055.HK

28 oct. 2024, 22:07 UTC

Résultats

China Southern Airlines 9-Mos Net CNY1.97B Vs. Net CNY1.32B >1055.HK

28 oct. 2024, 22:01 UTC

Résultats

CMOC Group: Higher Income From Mining and Processing Segment Supported Results >3993.HK

28 oct. 2024, 22:00 UTC

Résultats

CMOC Group 3Q Rev CNY51.94B, Up 15.5% on Year >3993.HK

28 oct. 2024, 21:59 UTC

Résultats

CMOC Group 3Q Net CNY2.86B , Up 64.1% on Year >3993.HK

28 oct. 2024, 21:38 UTC

Acquisitions, Fusions, Rachats

Fomento Economico Mexicano to Sell Plastics Solutions Operations to AMMI for MXN3.17B

28 oct. 2024, 21:23 UTC

Résultats

Waste Management Raises 2024 Revenue View to Up 6% >WM

28 oct. 2024, 21:21 UTC

Résultats

Waste Management 3Q Adj EPS $1.96 >WM

Comparaison

Variation de prix

Cara Therapeutics Inc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.2651 / 0.2727Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

51 / 389Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.